Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow Sells 4,646 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock traded up $0.20 on Friday, hitting $12.43. The company’s stock had a trading volume of 758,249 shares, compared to its average volume of 981,378. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $11.13 and a fifty-two week high of $18.07. The firm’s fifty day moving average price is $12.37 and its 200-day moving average price is $13.47. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares during the last quarter. SteelPeak Wealth LLC lifted its stake in shares of Day One Biopharmaceuticals by 9.8% in the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after purchasing an additional 1,550 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of Day One Biopharmaceuticals by 7.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company’s stock valued at $346,000 after purchasing an additional 1,805 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 5.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company’s stock valued at $454,000 after purchasing an additional 1,894 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at $27,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. Needham & Company LLC reissued a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. Finally, Bank of America decreased their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.